Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Revexepride. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR4 known ✓ | Q13639 | 10/20 | 0.53 |
| ▸ | HTR3A | P46098 | 2/20 | 0.53 |
| ▸ | HTR1A | P08908 | 1/20 | 0.53 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.53 |
| ▸ | ACHE | P22303 | 1/20 | 0.53 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.53 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.53 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.38 |
| ▸ | HTR3B | O95264 | 1/20 | 0.38 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.38 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.38 |
| ▸ | PTGES | O14684 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Revexepride SCHEMBL505586 | 1.00 | HTR4 (0.53) | HTR4HTR3AHTR1AADRA2CACHE | |
| Revexepride SCHEMBL505585 | 1.00 | HTR4 (0.53) | HTR4HTR3AHTR1AADRA2CACHE | |
| Revexepride SCHEMBL15773835 | 1.00 | HTR4 (0.53) | HTR4HTR3AHTR1AADRA2CACHE | |
| SCHEMBL7696893 | 0.88 | HTR4 (0.48) | HTR4HTR3AHTR1AADRA2CACHE | |
| SCHEMBL506339 | 0.85 | HTR4 (0.71) | HTR4HTR3AHTR1AADRA2CACHE | |
| SCHEMBL506340 | 0.85 | HTR4 (0.71) | HTR4HTR3AHTR1AADRA2CACHE | |
| SCHEMBL506341 | 0.85 | HTR4 (0.71) | HTR4HTR3AHTR1AADRA2CACHE | |
| SCHEMBL15773833 | 0.85 | HTR4 (0.71) | HTR4HTR3AHTR1AADRA2CACHE | |
| SCHEMBL3029923 | 0.84 | PTGES (0.40) | HTR4HTR3AHTR1AADRA2CACHE | |
| SCHEMBL3029927 | 0.84 | PTGES (0.40) | HTR4HTR3AHTR1AADRA2CACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260000674-A1 | PHARMACEUTICAL COMPOSITION | GEXVAL INC. (JP) | 2026-01-01 | — | — | US | claimed |
| EP-4548934-A1 | PHARMACEUTICAL COMPOSITION | Gexval Inc. (JP) | 2025-05-07 | — | — | EP | claimed |
| CN-119789869-A | Pharmaceutical composition | 嘉惟思远制药有限公司 | 2025-04-08 | — | — | CN | claimed |
| US-RE40793-E1 | Bicyclic benzamides of 3-or 4-substituted 4-(aminomethyl)-piperidine derivatives | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-06-23 | — | — | US | claimed |
| US-20070037850-A1 | used for the prophylaxis and therapeutic treatment of conditions involving decreased gastrointestinal motility, in particular decreased gastric emptying; gastrointestinal disorders | BOSMANS JEAN-PAUL RENE MARIE A | 2007-02-15 | — | — | US | claimed |
| US-20060142342-A1 | Bicyclic benzamides of 3- or 4-substituted 4-(aminomethyl)-piperidine derivatives | BOSMANS JEAN-PAUL RENE MARIE A | 2006-06-29 | — | — | US | claimed |
| US-20040096423-A1 | Use of a triple combination comprising a 5ht3 antagonist, a 5ht4agonist and a laxative for promoting intestinal lavage | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-05-20 | — | — | US | claimed |
| US-20040058958-A1 | Bicyclic benzamides of 3- or 4-substituted 4-(aminomethyl)-piperidine derivatives | BOSMANS JEAN-PAUL RENE MARIE A (BE) | 2004-03-25 | — | — | US | claimed |
| US-6635643-B2 | For treating conditions which are related to impairment of gastric emptying | JANSSEN PHARMACEUTICA, N.V. (BE) | 2003-10-21 | — | — | US | claimed |
| EP-1347779-A2 | USE OF A TRIPLE COMBINATION COMPRISING A 5HT3 ANTAGONIST, A 5HT4 AGONIST AND A LAXATIVE FOR PROMOTING INTESTINAL LAVAGE | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-10-01 | — | — | EP | claimed |
| EP-0991410-B1 | GASTROKINETIC BICYCLIC BENZAMIDES OF 3- OR 4-SUBSTITUTED 4-(AMINOMETHYL)-PIPERIDINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2002-10-30 | — | — | EP | claimed |
| US-20020086879-A1 | Bicyclic benzamides of 3- or 4-substituted 4-(aminomethyl)-piperidine derivatives | BOSMANS JEAN-PAUL RENE MARIE A (BE) | 2002-07-04 | — | — | US | claimed |
| WO-2002041918-A2 | USE OF A TRIPLE COMBINATION COMPRISING A 5HT3 ANTAGONIST, A 5HT4 AGONIST AND A LAXATIVE FOR PROMOTING INTESTINAL LAVAGE | JANSSEN PHARMACEUTICA N.V. (BE) | 2002-05-30 | — | — | WO | claimed |
| US-20260000674-A1 | PHARMACEUTICAL COMPOSITION | GEXVAL INC. (JP) | 2026-01-01 | — | — | US | disclosed |
| EP-4548934-A1 | PHARMACEUTICAL COMPOSITION | Gexval Inc. (JP) | 2025-05-07 | — | — | EP | disclosed |
| CN-119789869-A | Pharmaceutical composition | 嘉惟思远制药有限公司 | 2025-04-08 | — | — | CN | disclosed |
| EP-1347779-A2 | USE OF A TRIPLE COMBINATION COMPRISING A 5HT3 ANTAGONIST, A 5HT4 AGONIST AND A LAXATIVE FOR PROMOTING INTESTINAL LAVAGE | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-10-01 | — | — | EP | disclosed |
| EP-0991410-B1 | GASTROKINETIC BICYCLIC BENZAMIDES OF 3- OR 4-SUBSTITUTED 4-(AMINOMETHYL)-PIPERIDINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2002-10-30 | — | — | EP | disclosed |
| US-20020086879-A1 | Bicyclic benzamides of 3- or 4-substituted 4-(aminomethyl)-piperidine derivatives | BOSMANS JEAN-PAUL RENE MARIE A (BE) | 2002-07-04 | — | — | US | disclosed |
| WO-2002041918-A2 | USE OF A TRIPLE COMBINATION COMPRISING A 5HT3 ANTAGONIST, A 5HT4 AGONIST AND A LAXATIVE FOR PROMOTING INTESTINAL LAVAGE | JANSSEN PHARMACEUTICA N.V. (BE) | 2002-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142342-A1 | Bicyclic benzamides of 3- or 4-substituted 4-(aminomethyl)-piperidine derivatives | HRH2, HRH4, HRH1 | HTR4 248/4885HTR3A 555/4885HTR1A 136/4885 |
| US-20260000674-A1 | PHARMACEUTICAL COMPOSITION | HTR4, IL4, FFAR4 | HTR4 1/4885HTR3A 14/4885HTR1A 61/4885 |
| US-20070037850-A1 | used for the prophylaxis and therapeutic treatment of conditions involving decreased gastrointestinal motility, in particular decreased gastric emptying; gastrointestinal disorders | HRH2, HRH4, GIPR | HTR4 565/4885HTR3A 756/4885HTR1A 380/4885 |
| US-20020086879-A1 | Bicyclic benzamides of 3- or 4-substituted 4-(aminomethyl)-piperidine derivatives | CBR1, ALK, CBR3 | HTR4 257/4885HTR3A 664/4885HTR1A 353/4885 |
| US-20040058958-A1 | Bicyclic benzamides of 3- or 4-substituted 4-(aminomethyl)-piperidine derivatives | ALK, HRH2, CBR1 | HTR4 149/4885HTR3A 592/4885HTR1A 231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.